Open Orphan PLC

22 July 2021

22 June 2021


("Open Orphan" or the "Company")

The New England Journal of Medicine (NEJM) publishes editorial relating to

Human Challenge Programme

Open Orphan (AIM: ORPH), a rapidly growing specialist clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, confirms that an editorial opinion piece regarding the UK Government's Human Challenge Programme has been published in the latest edition of the New England Journal of Medicine (NEJM).

The piece, titled 'Establishing the Model during an Evolving Pandemic', explores the extensive preliminary review process which was commissioned by the UK Government and delivered by the coalition involved in the COVID-19 Human Challenge Programme to justify the research and manage and minimise the risks associated with the trial, as well as arguments supporting the inclusion of a SARS-CoV-2 human challenge research program as part of the pandemic response.

The Human Challenge Programme, part of the UK Government's Vaccine Taskforce, is a collaboration between the UK Government, the Royal Free London NHS Foundation Trust, Imperial College London and hVIVO , a subsidiary of Open Orphan, to deliver the world's first human challenge study for COVID-19.

In human challenge studies, a small number of healthy volunteers in a controlled setting are exposed to an infectious agent, in this instance, COVID-19, for scientists and clinicians to assess how effective vaccines or treatments are against the disease and identify any side effects.

The NEJM is recognised as the world's leading medical journal and website. Published continuously for over 200 years, the NEJM delivers high-quality, peer-reviewed research and interactive clinical content to physicians, educators, researchers, and the global medical community. The publication's mission is to publish the best research and information at the intersection of biomedical science and clinical practice and to present this information in understandable, clinically useful formats that inform health care practice and improve patient outcomes.

Cathal Friel, Executive Chairman of Open Orphan plc, commented: "We are delighted to see support for the COVID-19 Human Challenge Programme in a publication such as the New England Journal of Medicine. The piece articulates the considerable review process commissioned by the UK Government and delivered by hVIVO, in collaboration with the Royal Free London NHS Foundation Trust , and Imperial College London. We believe the UK Government's COVID-19 Human Challenge Programme will play a vital role in trialling the vaccines and antivirals which continue support our effective pandemic response in the UK and abroad. "

For further information please contact:

 Open Orphan plc                                                       +353 (0) 1 644 0007 
 Cathal Friel, Executive Chairman 
 Arden Partners plc (Nominated Adviser 
  and Joint Broker)                                                   +44 (0) 20 7614 5900 
 John Llewellyn-Lloyd / Richard Johnson 
  / Oscair McGrath 
 finnCap plc (Joint Broker)                                           +44 (0) 20 7220 0500 
 Geoff Nash / James Thompson/ Richard 
 Davy (Euronext Growth Adviser and Joint 
  Broker)                                                              +353 (0) 1 679 6363 
 Anthony Farrell 
 Walbrook PR (Financial PR & IR)          +44 (0)20 7933 8780 or openorphan@walbrookpr.com 
 Paul McManus / Louis Ashe-Jepson                      +44 (0)7980 541 893 / 07747 515 393 
  / Sam Allen                                                              / 07502 558 258 

Notes to Editors

Open Orphan plc (London and Euronext: ORPH) is a rapidly growing pharmaceutical service/contract research company that is a world leader in testing vaccines and antivirals using human challenge clinical trials. The company provides services to Big Pharma, biotech and government/public health organisations.

Open Orphan runs challenge studies in London from both its 19-bedroom Whitechapel quarantine clinic, opened in February 2021, and its 24-bedroom QMB clinic with its highly specialised on-site virology and immunology laboratory. Open Orphan has a leading portfolio of eight human challenge study models for infectious and respiratory diseases and is developing a number of other models including the world's first COVID-19 human challenge study model as part of the Human Challenge Programme .

Building upon its many years of challenge studies and virology research, the Company is developing an in-depth database of infectious disease progression data. Based on the Company's Disease in Motion(R) platform, this unique dataset includes clinical, immunological, virological and digital (wearable) biomarkers. The Disease in Motion platform has many potential applications across a wide variety of end users including big technology, wearables, pharma and biotech companies. Following COVID-19 there is now a renewed interest and investment in infectious diseases.

Open Orphan's Paris office has been providing biometry, data management and statistics to its many European pharmaceutical clients for over 20 years. For over 15 years, the Company's Netherlands office has been providing drug development consultancy and services, including CMC (chemistry, manufacturing and controls), PK and medical writing, to a broad range of European clients. Both offices are now also fully integrated with the London office and working on challenge study contracts as well as supporting third party trial contracts .

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

July 22, 2021 02:00 ET (06:00 GMT)

Open Orphan (LSE:ORPH)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Open Orphan Charts.
Open Orphan (LSE:ORPH)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Open Orphan Charts.